Skip to main content
Top
Published in: BMC Urology 1/2024

Open Access 01-12-2024 | Bone Metastasis | Research

Establishment and validation of a nomogram for predicting overall survival of upper-tract urothelial carcinoma with bone metastasis: a population-based study

Authors: Jiasheng Hu, Haowen Gu, Dongxu Zhang, Min Wen, Zejun Yan, Baiyang Song, Chengxin Xie

Published in: BMC Urology | Issue 1/2024

Login to get access

Abstract

Background

Bone metastasis (BM) carries a poor prognosis for patients with upper-tract urothelial carcinoma (UTUC). This study aims to identify survival predictors and develop a prognostic nomogram for overall survival (OS) in UTUC patients with BM.

Methods

The Surveillance, Epidemiology, and End Results database was used to select patients with UTUC between 2010 and 2019. The chi-square test was used to assess the baseline differences between the groups. Kaplan–Meier analysis was employed to assess OS. Univariate and multivariate analyses were conducted to identify prognostic factors for nomogram establishment. An independent cohort was used for external validation of the nomogram. The discrimination and calibration of the nomogram were evaluated using concordance index (C-index), area under receiver operating characteristic curve (AUC), calibration curve, and decision curve analysis (DCA). All statistical analyses were performed using SPSS 23.0 and R software 4.2.2.

Results

The mean OS for UTUC patients with BM was 10 months (95% CI: 8.17 to 11.84), with 6-month OS, 1-year OS, and 3-year OS rates of 41%, 21%, and 3%, respectively. Multi-organ metastases (HR = 2.21, 95% CI: 1.66 to 2.95, P < 0.001), surgery (HR = 0.72, 95% CI: 0.56 to 0.91, P = 0.007), and chemotherapy (HR = 0.37, 95% CI: 0.3 to 0.46, P < 0.001) were identified as independent prognostic factors. The C-index was 0.725 for the training cohort and 0.854 for the validation cohort, and all AUC values were > 0.679. The calibration curve and DCA curve showed the accuracy and practicality of the nomogram.

Conclusions

The OS of UTUC patients with BM was poor. Multi-organ metastases was a risk factor for OS, while surgery and chemotherapy were protective factors. Our nomogram was developed and validated to assist clinicians in evaluating the OS of UTUC patients with BM.
Literature
1.
3.
go back to reference Raman JD, Messer J, Sielatycki JA, Hollenbeak CS. Incidence and survival of patients with carcinoma of the ureter and renal pelvis in the USA, 1973–2005. BJU Int. 2011;107(7):1059–64.CrossRefPubMed Raman JD, Messer J, Sielatycki JA, Hollenbeak CS. Incidence and survival of patients with carcinoma of the ureter and renal pelvis in the USA, 1973–2005. BJU Int. 2011;107(7):1059–64.CrossRefPubMed
4.
go back to reference Cheaib JG, Claus LE, Patel HD, Kates MR, Matoso A, Hahn NM, et al. Site of metastatic recurrence impacts prognosis in patients with high-grade upper tract urothelial carcinoma. Urol Oncol. 2021;39(1):74.e9-.e16.CrossRefPubMed Cheaib JG, Claus LE, Patel HD, Kates MR, Matoso A, Hahn NM, et al. Site of metastatic recurrence impacts prognosis in patients with high-grade upper tract urothelial carcinoma. Urol Oncol. 2021;39(1):74.e9-.e16.CrossRefPubMed
5.
go back to reference Zalay O, Yan M, Sigurdson S, Malone S, Vera-Badillo FE, Mahmud A. Adjuvant Radiotherapy for Upper Tract Urothelial Carcinoma: Systematic Review and Meta-Analysis. Curr Oncol. 2022;30(1):19–36.CrossRefPubMedPubMedCentral Zalay O, Yan M, Sigurdson S, Malone S, Vera-Badillo FE, Mahmud A. Adjuvant Radiotherapy for Upper Tract Urothelial Carcinoma: Systematic Review and Meta-Analysis. Curr Oncol. 2022;30(1):19–36.CrossRefPubMedPubMedCentral
6.
go back to reference Leow JJ, Orsola A, Chang SL, Bellmunt J. A contemporary review of management and prognostic factors of upper tract urothelial carcinoma. Cancer Treat Rev. 2015;41(4):310–9.CrossRefPubMed Leow JJ, Orsola A, Chang SL, Bellmunt J. A contemporary review of management and prognostic factors of upper tract urothelial carcinoma. Cancer Treat Rev. 2015;41(4):310–9.CrossRefPubMed
7.
go back to reference Zhou M, Zhang J, Chen X, Wang Z, Liang W. Clinical features and prognostic indicators in upper-tract urothelial carcinoma with bone metastasis. Front Surg. 2022;9: 928294.CrossRefPubMedPubMedCentral Zhou M, Zhang J, Chen X, Wang Z, Liang W. Clinical features and prognostic indicators in upper-tract urothelial carcinoma with bone metastasis. Front Surg. 2022;9: 928294.CrossRefPubMedPubMedCentral
8.
go back to reference Liang W, He J, Shen Y, Shen J, He Q, Zhang J, et al. Impact of Examined Lymph Node Count on Precise Staging and Long-Term Survival of Resected Non-Small-Cell Lung Cancer: A Population Study of the US SEER Database and a Chinese Multi-Institutional Registry. J Clin Oncol. 2017;35(11):1162–70.CrossRefPubMed Liang W, He J, Shen Y, Shen J, He Q, Zhang J, et al. Impact of Examined Lymph Node Count on Precise Staging and Long-Term Survival of Resected Non-Small-Cell Lung Cancer: A Population Study of the US SEER Database and a Chinese Multi-Institutional Registry. J Clin Oncol. 2017;35(11):1162–70.CrossRefPubMed
9.
go back to reference Wu J, Zhang H, Li L, Hu M, Chen L, Xu B, et al. A nomogram for predicting overall survival in patients with low-grade endometrial stromal sarcoma: A population-based analysis. Cancer Commun (Lond). 2020;40(7):301–12.CrossRefPubMed Wu J, Zhang H, Li L, Hu M, Chen L, Xu B, et al. A nomogram for predicting overall survival in patients with low-grade endometrial stromal sarcoma: A population-based analysis. Cancer Commun (Lond). 2020;40(7):301–12.CrossRefPubMed
10.
go back to reference Stone GW, Maehara A, Lansky AJ, de Bruyne B, Cristea E, Mintz GS, et al. A prospective natural-history study of coronary atherosclerosis. N Engl J Med. 2011;364(3):226–35.CrossRefPubMed Stone GW, Maehara A, Lansky AJ, de Bruyne B, Cristea E, Mintz GS, et al. A prospective natural-history study of coronary atherosclerosis. N Engl J Med. 2011;364(3):226–35.CrossRefPubMed
11.
go back to reference Kang SJ, Cho YR, Park GM, Ahn JM, Han SB, Lee JY, et al. Predictors for functionally significant in-stent restenosis: an integrated analysis using coronary angiography, IVUS, and myocardial perfusion imaging. JACC Cardiovasc Imaging. 2013;6(11):1183–90.CrossRefPubMed Kang SJ, Cho YR, Park GM, Ahn JM, Han SB, Lee JY, et al. Predictors for functionally significant in-stent restenosis: an integrated analysis using coronary angiography, IVUS, and myocardial perfusion imaging. JACC Cardiovasc Imaging. 2013;6(11):1183–90.CrossRefPubMed
12.
go back to reference Zhang X, Wang P, Qi K, Qiao Q, Jiang Y. The role of surgery on primary site in metastatic upper urinary tract urothelial carcinoma and a nomogram for predicting the survival of patients with metastatic upper urinary tract urothelial carcinoma. Cancer Med. 2021;10(22):8079–90.CrossRefPubMedPubMedCentral Zhang X, Wang P, Qi K, Qiao Q, Jiang Y. The role of surgery on primary site in metastatic upper urinary tract urothelial carcinoma and a nomogram for predicting the survival of patients with metastatic upper urinary tract urothelial carcinoma. Cancer Med. 2021;10(22):8079–90.CrossRefPubMedPubMedCentral
13.
go back to reference Leow JJ, Chong KT, Chang SL, Bellmunt J. Upper tract urothelial carcinoma: a different disease entity in terms of management. ESMO open. 2016;1(6):e000126.CrossRefPubMed Leow JJ, Chong KT, Chang SL, Bellmunt J. Upper tract urothelial carcinoma: a different disease entity in terms of management. ESMO open. 2016;1(6):e000126.CrossRefPubMed
14.
go back to reference Tsuda Y, Nakagawa T, Shinoda Y, Kanatani A, Kawai T, Taguchi S, et al. Skeletal-related events and prognosis in urothelial cancer patients with bone metastasis. Int J Clin Oncol. 2017;22(3):548–53.CrossRefPubMed Tsuda Y, Nakagawa T, Shinoda Y, Kanatani A, Kawai T, Taguchi S, et al. Skeletal-related events and prognosis in urothelial cancer patients with bone metastasis. Int J Clin Oncol. 2017;22(3):548–53.CrossRefPubMed
15.
go back to reference Owari T, Miyake M, Nakai Y, Morizawa Y, Itami Y, Hori S, et al. Clinical Features and Risk Factors of Skeletal-Related Events in Genitourinary Cancer Patients with Bone Metastasis: A Retrospective Analysis of Prostate Cancer, Renal Cell Carcinoma, and Urothelial Carcinoma. Oncology. 2018;95(3):170–8.CrossRefPubMed Owari T, Miyake M, Nakai Y, Morizawa Y, Itami Y, Hori S, et al. Clinical Features and Risk Factors of Skeletal-Related Events in Genitourinary Cancer Patients with Bone Metastasis: A Retrospective Analysis of Prostate Cancer, Renal Cell Carcinoma, and Urothelial Carcinoma. Oncology. 2018;95(3):170–8.CrossRefPubMed
16.
go back to reference Owari T, Miyake M, Nakai Y, Tanaka N, Itami Y, Hirao S, et al. External validation of a genitourinary cancer-specific prognostic scoring system to predict survival for patients with bone metastasis (modified B-FOM scoring model): Comparison with other scoring models in terms of accuracy. J Bone Oncol. 2021;26:100344.CrossRefPubMed Owari T, Miyake M, Nakai Y, Tanaka N, Itami Y, Hirao S, et al. External validation of a genitourinary cancer-specific prognostic scoring system to predict survival for patients with bone metastasis (modified B-FOM scoring model): Comparison with other scoring models in terms of accuracy. J Bone Oncol. 2021;26:100344.CrossRefPubMed
17.
go back to reference Galsky MD, Chen GJ, Oh WK, Bellmunt J, Roth BJ, Petrioli R, et al. Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma. Ann Oncol. 2012;23(2):406–10.CrossRefPubMed Galsky MD, Chen GJ, Oh WK, Bellmunt J, Roth BJ, Petrioli R, et al. Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma. Ann Oncol. 2012;23(2):406–10.CrossRefPubMed
18.
go back to reference Alqaisi HA, Stecca C, Veitch ZW, Riromar J, Kaiser J, Fallah-Rad N, et al. The prognostic impact of bone metastasis in patients with metastatic urothelial carcinoma treated with first-line platinum-based chemotherapy. Ther Adv Med Oncol. 2022;14:17588359221094880.CrossRefPubMedPubMedCentral Alqaisi HA, Stecca C, Veitch ZW, Riromar J, Kaiser J, Fallah-Rad N, et al. The prognostic impact of bone metastasis in patients with metastatic urothelial carcinoma treated with first-line platinum-based chemotherapy. Ther Adv Med Oncol. 2022;14:17588359221094880.CrossRefPubMedPubMedCentral
19.
go back to reference Leow JJ, Chong YL, Chang SL, Valderrama BP, Powles T, Bellmunt J. Neoadjuvant and Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: A 2020 Systematic Review and Meta-analysis, and Future Perspectives on Systemic Therapy. Eur Urol. 2021;79(5):635–54.CrossRefPubMed Leow JJ, Chong YL, Chang SL, Valderrama BP, Powles T, Bellmunt J. Neoadjuvant and Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: A 2020 Systematic Review and Meta-analysis, and Future Perspectives on Systemic Therapy. Eur Urol. 2021;79(5):635–54.CrossRefPubMed
20.
go back to reference Seisen T, Jindal T, Karabon P, Sood A, Bellmunt J, Rouprêt M, et al. Efficacy of Systemic Chemotherapy Plus Radical Nephroureterectomy for Metastatic Upper Tract Urothelial Carcinoma. Eur Urol. 2017;71(5):714–8.CrossRefPubMed Seisen T, Jindal T, Karabon P, Sood A, Bellmunt J, Rouprêt M, et al. Efficacy of Systemic Chemotherapy Plus Radical Nephroureterectomy for Metastatic Upper Tract Urothelial Carcinoma. Eur Urol. 2017;71(5):714–8.CrossRefPubMed
21.
go back to reference Paciotti M, Nguyen DD, Modonutti D, Haeuser L, Lipsitz S, Mossanen M, et al. Impact of high-intensity local treatment on overall survival in stage IV upper tract urothelial carcinoma. Urol Oncol. 2021;39(7):436.e1-436.e10.CrossRefPubMed Paciotti M, Nguyen DD, Modonutti D, Haeuser L, Lipsitz S, Mossanen M, et al. Impact of high-intensity local treatment on overall survival in stage IV upper tract urothelial carcinoma. Urol Oncol. 2021;39(7):436.e1-436.e10.CrossRefPubMed
22.
go back to reference Sprave T, Verma V, Förster R, Schlampp I, Hees K, Bruckner T, et al. Bone density and pain response following intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy for vertebral metastases - secondary results of a randomized trial. Radiat Oncol. 2018;13(1):212.CrossRefPubMedPubMedCentral Sprave T, Verma V, Förster R, Schlampp I, Hees K, Bruckner T, et al. Bone density and pain response following intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy for vertebral metastases - secondary results of a randomized trial. Radiat Oncol. 2018;13(1):212.CrossRefPubMedPubMedCentral
23.
go back to reference Manig L, Käsmann L, Janssen S, Rades D. Predicting Survival After Irradiation of Metastases from Transitional Carcinoma of the Bladder. Anticancer Res. 2016;36(12):6663–5.CrossRefPubMed Manig L, Käsmann L, Janssen S, Rades D. Predicting Survival After Irradiation of Metastases from Transitional Carcinoma of the Bladder. Anticancer Res. 2016;36(12):6663–5.CrossRefPubMed
24.
25.
go back to reference Kolawa A, D’Souza A, Tulpule V. Overview, Diagnosis, and Perioperative Systemic Therapy of Upper Tract Urothelial Carcinoma. Cancers (Basel). 2023;15(19):4813.CrossRefPubMed Kolawa A, D’Souza A, Tulpule V. Overview, Diagnosis, and Perioperative Systemic Therapy of Upper Tract Urothelial Carcinoma. Cancers (Basel). 2023;15(19):4813.CrossRefPubMed
26.
go back to reference Rouprêt M, Seisen T, Birtle AJ, Capoun O, Compérat EM, Dominguez-Escrig JL, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update. Eur Urol. 2023;84(1):49–64.CrossRefPubMed Rouprêt M, Seisen T, Birtle AJ, Capoun O, Compérat EM, Dominguez-Escrig JL, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update. Eur Urol. 2023;84(1):49–64.CrossRefPubMed
27.
go back to reference Kaag MG, O’Malley RL, O’Malley P, Godoy G, Chen M, Smaldone MC, et al. Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy. Eur Urol. 2010;58(4):581–7.CrossRefPubMedPubMedCentral Kaag MG, O’Malley RL, O’Malley P, Godoy G, Chen M, Smaldone MC, et al. Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy. Eur Urol. 2010;58(4):581–7.CrossRefPubMedPubMedCentral
28.
go back to reference Ni K, Yu C, Wang H, Zhu S, Yu S, Li G. Immunotherapy with or without targeted therapy for metastatic upper tract urothelial carcinoma: case report and literature review. Heliyon. 2023;9(5):e15813.CrossRefPubMedPubMedCentral Ni K, Yu C, Wang H, Zhu S, Yu S, Li G. Immunotherapy with or without targeted therapy for metastatic upper tract urothelial carcinoma: case report and literature review. Heliyon. 2023;9(5):e15813.CrossRefPubMedPubMedCentral
29.
go back to reference Wang Z, Cheng Y, Chen S, Shao H, Chen X, Wang Z, et al. Novel prognostic nomograms for female patients with breast cancer and bone metastasis at presentation. Ann Transl Med. 2020;8(5):197.CrossRefPubMedPubMedCentral Wang Z, Cheng Y, Chen S, Shao H, Chen X, Wang Z, et al. Novel prognostic nomograms for female patients with breast cancer and bone metastasis at presentation. Ann Transl Med. 2020;8(5):197.CrossRefPubMedPubMedCentral
30.
go back to reference Liu L, Yuan H, Wang Q, Li C. Effects of Different Organ Metastases on the Prognosis of Stage IV Urothelial Carcinoma of the Bladder. J Oncol. 2022;2022:8594022.CrossRefPubMedPubMedCentral Liu L, Yuan H, Wang Q, Li C. Effects of Different Organ Metastases on the Prognosis of Stage IV Urothelial Carcinoma of the Bladder. J Oncol. 2022;2022:8594022.CrossRefPubMedPubMedCentral
Metadata
Title
Establishment and validation of a nomogram for predicting overall survival of upper-tract urothelial carcinoma with bone metastasis: a population-based study
Authors
Jiasheng Hu
Haowen Gu
Dongxu Zhang
Min Wen
Zejun Yan
Baiyang Song
Chengxin Xie
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Urology / Issue 1/2024
Electronic ISSN: 1471-2490
DOI
https://doi.org/10.1186/s12894-024-01488-7

Other articles of this Issue 1/2024

BMC Urology 1/2024 Go to the issue